非酒精性脂肪性肝炎新药研发:一个未被满足的临床需求

Research and development of new drugs for nonalcoholic steatohepatitis:An unmet need in clinical practice

随着全球范围内病毒性肝炎得到有效控制,非酒精性脂肪性肝炎(NASH)在未来10年将成为肝移植的主要病因。NASH患者数量庞大,但至今尚无任何权威机构批准的治疗药物上市,这代表着一个巨大的尚未满足的临床需求。NASH复杂的发病机制、疾病异质性、诊断障碍以及治疗终点的选择等给新药研发带来了巨大挑战。

With the effective control of viral hepatitis around the world,nonalcoholic steatohepatitis(NASH)will become the main cause of liver transplantation in the next ten years.There is a huge number of NASH patients,but currently no drug has been approved by authorities,which represents a large unmet need in clinical practice.The complex pathogenesis of NASH,heterogeneity of this disease,difficulties in diagnosis,and selection of treatment endpoints have brought great challenges to the research and development of new drugs.